Interview with the Co-Founder and CEO: GenSight Biologics (EPA:SIGHT)
Bernard Gilly, Ph.D., a Co-Founder of GenSight Biologics, has served as its Chief Executive Officer since its founding. From creation through to 2016, Dr. Gilly served as Chairman of the board of directors. From 2011 through 2014, he served as Chief Executive Officer at Pixium Vision, and from which date, he has served as nonexecutive Chairman of the board of directors. In addition, he currently serves on the boards of Prophesee S.A. — formerly Chronocam — and Gecko Biomedical. From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals S.A., or Fovea, a privately funded biotech company, which was later acquired by Sanofi. He then became Senior Vice President of the Ophthalmology Division of Sanofi and served in that role until March 2012. Profile
Word count: 2,925
TWST: What is the best way to define what GenSight Biologics is?
Dr. Gilly: GenSight Biologics is a Paris-based biotechnology company